ICAP Grand Rounds - Long-Acting Injectable Cabotegravir for HIV Prevention: Promises and Pitfalls

As regulatory approvals for long-acting, injectable cabotegravir (CAB-LA) as pre-exposure prophylaxis (PrEP) against HIV move forward, Raphael J. Landovitz, MD, MSc, HPTN 03 Protocol Chair, discusses findings from the randomized controlled trial and ongoing open-label extension phases of the studies, including some thoughts on opportunities and challenges of clinical implementation in this grand rounds.